Privacy voorkeur

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


 

ASCO GU 2018: Renal Cell Carcinoma News Program

This year the ASCO Genitourinary Cancers Symposium took place in San Francisco from February 8th - 10th. In this Renal Cell Carcinoma News Program, we focus on the highlights for RCC at this congress. Moderator Catherine Hood and a panel of international experts discuss the following topics: Adjuvant systemic therapy Cabozantinib in the first line treatment of metastatic RCC The NIVOREN trial that investigates nivolumab in a ‘real world setting’ Combination treatments with VEGF and PD1/PD-L1 inhibition Advances in treatment for papillary RCC Speakers: Prof. Joaquim Bellmunt, MD, medical oncologist, Dana-Farber/Brigham and Women's Cancer Center, Boston Daniel George, MD, medical oncologist, Duke Cancer Center, Durham Jeanny Aragon-Ching, MD, medical oncologist, Inova Fairfax hospital, Fairfax Sumanta Pal, MD, medical oncologist, City of Hope Comprehensive Cancer Center, Duarte Moderator: Catherine Hood

  • 00:39:40
  • 22 Mar 2018
 

WCM 2017 Highlights: Biomarker immunotherapy

The 9th World Congress of Melanoma (WCM) was held in Brisbane, Australia, from 18 to 21 October. In a series of interviews medical professionals from all over the world discussed the latest developments in the field of melanoma. This highlight consists of the following parts: Michele Teng, PhD – research scientist, QIMR Berghofer Medical Research Institute, Brisbane, Australia: Why does immunotherapy works so well for melanoma? Prof. Levesque Mitchell, MD – dermatologist, University of Zurich Hospital, Zürich, Switzerland: High dimensional single-cell analysis identifies classical monocyte frequencies to be predictive of PFS to anti-PD-1 immunotherapy Prof. Nikolas Haass, MD – dermatologist, University of Queensland, Brisbane, Australia: Tumor heterogeneity, plasticity and drug resistance

  • 00:16:35
  • 22 Mar 2018
 

ESMO 2017 in-depth: KEYNOTE-040 trial

This year the ESMO congress took place in Madrid from 8 - 12 September. E. This phase III trial evaluated the efficacy of checkpoint inhibitor pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma after platinum-based chemotherapy.

  • 00:08:50
  • 22 Mar 2018
 

Clinical updates from the EHA 2017 part 1

The 22nd European Hematology Association (EHA) took place in Madrid, Spain, on 22-25 June 2017. An international multidisciplinary panel discussed a selection of topics and new data on hematology during a live program. They gave an answer to what this newly acquired knowledge means for clinical practice. Topics New immunotherapy data for lymphoma The mechanisms behind iron overload New diagnostic markers for ITP Speakers Alicia Rovó, MD – hematologist, University Hospital of Bern, Bern, Switzerland Sigrid Machherndl-Spandl, MD – hematologist, Elisabethinen Hospital, Linz, Austria Moderator Prof. Harry Schouten, MD – hematologist, Maastricht UMC+, Maastricht, The Netherlands

  • 00:50:48
  • 22 Mar 2018

Click here to select your areas of interest

Areas of interest

Select to filter on program types

Quarterly focus

September 6th: Quarterly Focus on Genitourinary Cancer | RCC

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this second episode, two pivotal, international publications on Renal Cell Carcinoma from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During the live broadcast on Thursday September 6th 8.30-9.30 PM CEST you have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The expert panel consist of: Prof. John Haanen, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam Hans Westgeest, MD, medical oncologist, Amphia Ziekenhuis, Breda Astrid van der Veldt, MD, PhD, medical oncologist, Erasmus MC, Rotterdam Provisional program: Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma N Engl J Med 378, 2018 IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC) J Clin Oncol 36, 2018 This program is editorially independent and is financially supported by Astellas, BMS, MSD and Roche.

Congress news

ASCO 2018 Rechallenge with bevacizumab in ovarian cancer

Dr. Sandro Pignata, oncologist and president of the Multicentre Italian Trial in Ovarian cancer (MITO) group, explains the results of the MITO 16b trial. This study evaluated whether the addition of bevacizumab to a platinum-based chemotherapy prolongs survival for recurrent ovarian cancer patients who had already received it during first line.

Congress news

ASCO 2018 Results of the TAILORx trial

Joseph Sparano, oncologist at Montefiore Medical Center, explains the results of the TAILORx trial, which he presented during the plenary session at ASCO 2018. This trial attempted to incorporate a gene expression test into clinic decision making for hormone receptor positive breast cancer.

Quarterly focus

E-learning: Quarterly Focus on Hemato-Oncology | Highlights in AML 2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Three high-impact, recent international publications on two main topics in AML will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The studio expert panel consists of: Prof. Gert Ossenkoppele, MD, PhD, hematologist, VUmc Amsterdam, The Netherlands Bas Wouters, MD, PhD, hematologist, ErasmusMC Rotterdam, The Netherlands Peter Valk, PhD, molecular biologist in hematology, ErasmusMC Rotterdam, The Netherlands Live video guests: Courtney Dinardo, MD, hemato-oncologist, MD Anderson Cancer Center, Houston, US Eytan Stein, MD, hemato-oncologist, MSKCC, New York, US Prof. Christian Thiede MD, PhD, professor in molecular hematology, Universitätsklinikum Dresden, Germany

Quarterly focus

E-learning: Quarterly Focus on Genitourinary Cancer | Prostate Cancer

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Two pivotal, international publications from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: André Bergman MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam Martijn Lolkema MD, PhD, medical oncologist, Erasmus MC, Rotterdam Niven Mehra MD, PhD, medical oncologist, Radboudumc, Nijmegen Program: Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial J Clin Oncol 36, 2018 Speaker: Prof. Gert De Meerleer MD, PhD, radiation oncologist, UZ Leuven, Belgium Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide J Clin Oncol 35, 2017 Speaker: Jun Luo MD, PhD, cell and molecular biologist, Brady Urological Institute, US

Quarterly focus

E-learning: Quarterly Focus on Breast Cancer

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not have always sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks.eu/OncologyTV has developed a new program format, the 'Quarterly Focus', which brings together an expert panel and the authors of relevant, selected publications in an innovative way to explain and discuss the new data. Two pivotal, international publications from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the unique possibility to gain more insight into the selected publications and to interact with the expert panel and the authors. The expert panel consists of: Gabe Sonke, MD, Ph.D, medical oncologist, NKI-AVL Amsterdam, Netherlands Ester Siemerink, MD, Ph.D, medical oncologist, Ziekenhuis Groep Twente, Hengelo/Almelo, Netherlands Rianne Oosterkamp, MD, medical oncologist, Haaglanden Medisch Centrum, Den Haag, Netherlands Invited speakers: Prof. George Sledge, MD, medical oncologist Stanford University School of Medicine, California, US MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy J Clin Oncol, 2017 Prof. Laura van 't Veer, molecular biologist UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades JAMA Oncol, 2017

Quarterly focus

Quarterly Focus on Hemato-Oncology | Highlights in AML

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not have always sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks.eu has developed a new program format, the 'Quarterly Focus, which brings together an expert panel and the authors of relevant, selected publications in an innovative way to explain and discuss the new data. The selection for the first edition of Quarterly Focus on Hemato-Oncology has been made by prof. dr. Gert Ossenkoppele, VUmc Amsterdam, Netherlands. Three pivotal, international publications from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the unique possibility to gain more insight into the selected publications and to interact with the expert panel and the authors. The expert panel consists of: Prof. Gert Ossenkoppele, MD, hematologist, VUmc, Amsterdam, Netherlands; Prof. Gerwin Huls, MD, hematologist, UMCG, Groningen; Netherlands; Peter Valk, Ph.D., molecular biologist, Erasmus MC, Rotterdam, Netherlands. Selected publications Quarterly Hemato-Oncology: Midostaurin plus chemotherapy for acute myeloid leukemia with FLT mutation N Engl J Med 2017 Prof. Richard Schlenk, MD, hematologist TP53 and decitabine in AML and myelodysplastic syndromes N Engl J Med 2016 Dr. John S. Welch, MD, Ph.D., hematologist Precision Oncology in acute myeloid leukemia using a knowledge bank approach. Nature Genetics, January 2017 Elli Papaemmanuil, Ph.D., molecular geneticist Accreditation: This program will be submitted for accreditation at the EBAH and Dutch NIV.

Congress news

ASCO GU 2018: Renal Cell Carcinoma News Program

This year the ASCO Genitourinary Cancers Symposium took place in San Francisco from February 8th - 10th. In this Renal Cell Carcinoma News Program, we focus on the highlights for RCC at this congress. Moderator Catherine Hood and a panel of international experts discuss the following topics: Adjuvant systemic therapy Cabozantinib in the first line treatment of metastatic RCC The NIVOREN trial that investigates nivolumab in a ‘real world setting’ Combination treatments with VEGF and PD1/PD-L1 inhibition Advances in treatment for papillary RCC Speakers: Prof. Joaquim Bellmunt, MD, medical oncologist, Dana-Farber/Brigham and Women's Cancer Center, Boston Daniel George, MD, medical oncologist, Duke Cancer Center, Durham Jeanny Aragon-Ching, MD, medical oncologist, Inova Fairfax hospital, Fairfax Sumanta Pal, MD, medical oncologist, City of Hope Comprehensive Cancer Center, Duarte Moderator: Catherine Hood

Congress news

ASCO GU 2018: PROs and HRQoL of LATITUDE

Dr. Kim Chi, medical oncologist at the BC Cancer Agency in Vancouver, summarizes the results of the LATITUDE trial and the recently published patient-reported outcomes and health-related quality of life.

Congress news

ASCO GU 2018: Progression after IO combination regimens mRCC

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined the clinical outcome of patients with metastatic renal cell carcinoma progressing on frontline immune-oncology based combination regimens.

Congress news

ASCO GU 2018: Oligoprogressive mRCC

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined what the impact was of switching systemic treatment after radiosurgery for oligoprogressive, metastatic renal cell carcinoma.

Congress news

WCM 2017 Highlights: Biomarker immunotherapy

The 9th World Congress of Melanoma (WCM) was held in Brisbane, Australia, from 18 to 21 October. In a series of interviews medical professionals from all over the world discussed the latest developments in the field of melanoma. This highlight consists of the following parts: Michele Teng, PhD – research scientist, QIMR Berghofer Medical Research Institute, Brisbane, Australia: Why does immunotherapy works so well for melanoma? Prof. Levesque Mitchell, MD – dermatologist, University of Zurich Hospital, Zürich, Switzerland: High dimensional single-cell analysis identifies classical monocyte frequencies to be predictive of PFS to anti-PD-1 immunotherapy Prof. Nikolas Haass, MD – dermatologist, University of Queensland, Brisbane, Australia: Tumor heterogeneity, plasticity and drug resistance